NASDAQ:IVA Inventiva Q1 2025 Earnings Report $3.33 +0.24 (+7.77%) As of 02:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileForecast Inventiva EPS ResultsActual EPSN/AConsensus EPS -$0.47Beat/MissN/AOne Year Ago EPSN/AInventiva Revenue ResultsActual RevenueN/AExpected Revenue$6.40 millionBeat/MissN/AYoY Revenue GrowthN/AInventiva Announcement DetailsQuarterQ1 2025Date5/23/2025TimeBefore Market OpensConference Call DateFriday, May 23, 2025Conference Call Time2:00AM ETConference Call ResourcesPress Release (6-K)Press ReleaseCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Press Release Inventiva Earnings HeadlinesInventiva S.A. reports Q1 resultsMay 23, 2025 | seekingalpha.comINVENTIVA: Inventiva reports 2025 First Quarter Financial InformationMay 23, 2025 | finanznachrichten.deThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?May 27, 2025 | Timothy Sykes (Ad)Inventiva reports 2025 First Quarter Financial Information¹May 23, 2025 | globenewswire.comResults of the Votes of the Combined Shareholders' General Meeting of May 22, 2025May 23, 2025 | globenewswire.comDescription of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler ChevreuxMay 22, 2025 | uk.finance.yahoo.comSee More Inventiva Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Inventiva? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inventiva and other key companies, straight to your email. Email Address About InventivaInventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.View Inventiva ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBooz Allen Hamilton Earnings: 3 Bullish Signals for BAH StockAdvance Auto Parts Jumps on Surprise Earnings BeatAlibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong Earnings Upcoming Earnings NVIDIA (5/28/2025)Synopsys (5/28/2025)Bank of Montreal (5/28/2025)Salesforce (5/28/2025)Haleon (5/28/2025)Costco Wholesale (5/29/2025)Marvell Technology (5/29/2025)Canadian Imperial Bank of Commerce (5/29/2025)Dell Technologies (5/29/2025)National Grid (5/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
